References
- Franck N, Barete S, Moguelet P, et al. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. J Clin Oncol 2010;28:640–642
- Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012;148:628–633
- Izakovic J, Büchner SA, Düggelin M, et al. Hair-like hyperkeratoses in patients with kidney transplants: a new cyclosporin side-effect. Hautarzt 1995;46:841–846
- Tay LK, Lim FL, Ng HJ, et al. Cutaneous follicular hyperkeratotic spicules-the first clinical sign of multiple myeloma progression or relapse. Int J Dermatol 2010;49:934–936
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245
- Digiovanna JJ, Mauro T, Milstone LM, et al. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther 2013;26:26–38
- Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010;8:47–59
- Kuijpers AL, Van Pelt JP, Bergers M, et al. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol 1998;139:380–389